All In Biotech

Drug Trial Radar · NCT05671835

Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

REVERT-IPF: A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

May 15, 2023

Primary completion

Aug 14, 2025

Study completion Aug 14, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • TTI-101Drug

    Orally via a tablet.

  • PlaceboDrug

    Orally via a tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with an Adverse Event (AE)Time frame: 16 weeks

Locations

28 sites in 1 country. Site status is shown where the registry gives one.

  • The Kirklin Clinic of University of Alabama Birmingham Hospital

    Birmingham, Alabama

  • University of California San Diego

    La Jolla, California

  • University of California Irvine (UCI) Health

    Orange, California

  • University of Colorado School of Medicine

    Aurora, Colorado

  • Saint Francis Sleep Allergy and Lung Institute

    Clearwater, Florida

  • University of Florida

    Gainesville, Florida

  • UHealth - University of Miami Health Systems

    Miami, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Medicine

    Chicago, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Tulane University School of Medicine

    New Orleans, Louisiana

  • The Lung Research Center

    Chesterfield, Missouri

  • New York University Langone Pulmonary and Critical Care Associates

    Brooklyn, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Pulmonix

    Greensboro, North Carolina

  • Salem Chest Specialists

    Winston-Salem, North Carolina

  • Saint Luke's University Hospital - Bethlehem

    Bethlehem, Pennsylvania

  • Penn State Health Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Temple University Hospital

    Philadelphia, Pennsylvania

  • The Medical University of South Carolina

    Charleston, South Carolina

  • Clinical Trials Center of Middle Tennessee

    Franklin, Tennessee

  • Baylor Scott & White Center for Advanced Heart & Lung Disease

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Texas Health Science Center at Houston (UT Health)

    Houston, Texas

  • Metroplex Pulmonary and Sleep Center

    McKinney, Texas

  • Inova Fairfax Medical Campus

    Falls Church, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.